CervoMed's dementia drug fails mid-stage trial, shares slump
CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary goals in a mid-stage clinical trial, sending the U.S. drug developer shares down 77% in early trading.
CervoMed's ex-Vertex drug fails to reduce dementia symptoms in phase 2 trial
CervoMed’s ex-Vertex drug has failed to reduce the severity of patients’ dementia in a phase 2 trial, halting plans for a late-stage study.
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets
CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies (DLB). The trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes (a measure of dementia severity) or any of its key secondary endpoints – change from baseline in Timed Up and Go (measures a person’s mobility,
CervoMed Shares Slide to All-Time Low After Study Failure
CervoMed shares collapsed Tuesday after the clinical-stage company reported a mid-stage study failure of its lead program. Shares of the Boston company were recently changing hands at $2.26, down 78%, after touching an all-time low of $2.20 early in the session.
CervoMed's dementia drug fails to meet mid-stage trial goals
U.S. drug developer CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary goals in a mid-stage clinical trial. The drug, neflamapimod,
CervoMed stock crashes 77% on failed study for dementia drug
Shares of CervoMed (NASDAQ:CRVO) plunged 77% Tuesday after the company said a Phase 2b study of its drug candidate neflamapimod for the treatment of dementia with Lewy bodies failed to meet its primary or key secondary endpoints.
CervoMed’s stock craters 77% after failed trial of treatment for rare brain disease
CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with ...
Hosted on MSN16h
D. Boral Capital Downgrades CervoMed (CRVO)
Fintel reports that on December 10, 2024, D. Boral Capital downgraded their outlook for CervoMed (NasdaqCM:CRVO) from Buy to ...
bovnews13h
CervoMed Inc (CRVO) Posted -118.68% Profit Margin Last Year—Can It Hold Up?
On Tuesday, CervoMed Inc (CRVO) stock saw a decline, ending the day at $2.16 which represents a decrease of $-8.09 or -78.93% from the prior close of $10.25. The stock opened at $2.53 and touched a ...
CervoMed price target lowered to $4 from $45 at Roth MKM
Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company has reported ...
Hosted on MSN17h
Chardan Capital Downgrades CervoMed (CRVO)
Fintel reports that on December 11, 2024, Chardan Capital downgraded their outlook for CervoMed (NasdaqCM:CRVO) from Buy to ...
CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint
CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet ...
CervoMed downgraded to Underweight from Overweight at Morgan Stanley
Morgan Stanley double downgraded CervoMed (CRVO) to Underweight from Overweight without a price target saying multiple questions remain for ...
ETF Daily News4d
HC Wainwright Forecasts CervoMed’s Q4 Earnings (NASDAQ:CRVO)
CervoMed Inc. (NASDAQ:CRVO – Free Report) – Equities researchers at HC Wainwright issued their Q4 2024 earnings estimates ...
devdiscourse1d
Drug Breakthroughs and Setbacks: A Week in Pharmaceutical Innovations
Recent headlines in health news spotlight several pharmaceutical developments: AbbVie's Parkinson's drug shows promise in ...